Can Ginkgo Bioworks’ synthetic biology venture reduce mycotoxins in animal feed, cut antibiotic use? – Genetic Literacy Project
Genetic Literacy Project |
Can Ginkgo Bioworks’ synthetic biology venture reduce mycotoxins in animal feed, cut antibiotic use?
Genetic Literacy Project “Synthetic biology also has great potential to help facilitate a reduction in antibiotic use through the production of a diverse range of feed ingredients that can support healthy gut function and immune health, such as bioactive peptides, prebiotics … |
Genetic Literacy Project |
Can Ginkgo Bioworks’ synthetic biology venture reduce mycotoxins in animal feed, cut antibiotic use?
Genetic Literacy Project “Synthetic biology also has great potential to help facilitate a reduction in antibiotic use through the production of a diverse range of feed ingredients that can support healthy gut function and immune health, such as bioactive peptides, prebiotics … |
Reuters |
Setback to Roche hopes for Tecentriq as fails key cancer trial
Reuters Tecentriq is already approved for some lung cancer patients and bladder cancer, but Roche, the world’s biggest oncology drugs maker, is running multiple trials of the immunotherapy as it seeks to expand it range of uses. Trials against some lung … Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug CombosXconomy Another IO knockback as Tecentriq combo fails phase III trialPMLiVE |
Technology Networks |
CAR T Cell Therapy Shows Promise in Acute Myeloid Leukemia
Technology Networks Chimeric Antigen Receptor T–cell therapy, also known as CAR T therapy, was named the biggest research breakthrough of 2017 by the American Society of Clinical Oncology. The personal gene therapy utilizes a patient’s own immune cells to fight cancer. |